Novocure GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.5M
Doctors Paid
299
Transactions
2,128
2024 Total
$4.8M
Payment Breakdown by Category
Research$13.1M (97.1%)
Consulting$280,924 (2.1%)
Travel$3,112 (0.0%)
Food & Beverage$2,312 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.1M | 1,776 | 97.1% |
| Consulting Fee | $280,924 | 58 | 2.1% |
| Honoraria | $111,907 | 261 | 0.8% |
| Travel and Lodging | $3,112 | 8 | 0.0% |
| Food and Beverage | $2,312 | 25 | 0.0% |
Payments by Type
Research
$13.1M
1,776 transactions
General
$398,256
352 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma | $9.9M | 0 | 1,570 |
| EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) | $350,702 | 0 | 57 |
| EF-36 A Pilot, Randomized,Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for First LineTreatment of Advanced or Metastatic Non-Small Cell Lung Cancer | $306,456 | 0 | 41 |
| EF-36 A pilot, single arm, open-label study of Tumor Treating Fields (TTFields,150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer | $268,032 | 0 | 17 |
| EF-36 a pilot, randomized, open-label study evaluating the safety and effectiveness of Tumor Treating Fields (TTFields) with pembrolizumab for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). | $211,421 | 0 | 44 |
| MAXPOINTTM software beta version testing protocol | $155,000 | 0 | 12 |
| Determining the efficacy of using the Inovivo system to enhance the efficacy of checkpoint inhibitor treatment in glioblastoma mouse models | $118,500 | 0 | 1 |
| EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma | $25,435 | 0 | 3 |
| EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | $18,394 | 0 | 2 |
| A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant withpembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer | $13,500 | 0 | 1 |
| EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. | $1,897 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Radiation Oncology | $157,002 | 7 | $22,429 |
| Medical Oncology | $55,490 | 50 | $1,110 |
| Neurological Surgery | $52,500 | 1 | $52,500 |
| Gynecologic Oncology | $40,660 | 9 | $4,518 |
| Hematology & Oncology | $37,170 | 134 | $277.38 |
| Obstetrics & Gynecology | $17,801 | 5 | $3,560 |
| Thoracic Surgery (Cardiothoracic Vascular Surgery) | $9,452 | 1 | $9,452 |
| Internal Medicine | $8,261 | 40 | $206.53 |
| Neurology | $7,238 | 5 | $1,448 |
| Dermatology | $2,400 | 1 | $2,400 |
| Specialist | $1,850 | 9 | $205.56 |
| Hematology | $1,600 | 8 | $200.00 |
| Family | $1,100 | 5 | $220.00 |
| Student in an Organized Health Care Education/Training Program | $1,050 | 5 | $210.00 |
| Emergency Medicine | $634.30 | 2 | $317.15 |
| Nurse Practitioner | $500.00 | 2 | $250.00 |
| Hospice and Palliative Medicine | $450.00 | 2 | $225.00 |
| Surgery | $400.00 | 1 | $400.00 |
| Hospitalist | $338.89 | 2 | $169.45 |
| Critical Care Medicine | $316.67 | 1 | $316.67 |
| Pulmonary Disease | $291.67 | 1 | $291.67 |
| Adult Health | $250.00 | 1 | $250.00 |
| Physician Assistant | $250.00 | 1 | $250.00 |
| Registered Nurse | $250.00 | 1 | $250.00 |
| Geriatric Medicine | $200.00 | 1 | $200.00 |
| Medical | $200.00 | 1 | $200.00 |
| Oncology | $200.00 | 1 | $200.00 |
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Howard West, Md, MD | Medical Oncology | Duarte, CA | $2,400 | $0 |
| Thomas Herzog, M.d, M.D | Gynecologic Oncology | Cincinnati, OH | $2,400 | $0 |
| Fred Hirsh, M.d, M.D | Dermatology | Cleveland, OH | $2,400 | $0 |
| Alexander Olawaiye | Gynecologic Oncology | Pittsburgh, PA | $2,400 | $0 |
| Leslie Randall, Md, MD | Obstetrics & Gynecology | Fairfax, VA | $2,400 | $0 |
| Neal Ready, Md, MD | Medical Oncology | Durham, NC | $2,400 | $0 |
| Stephen Rosenberg | Radiation Oncology | Madison, WI | $2,400 | $0 |
| Dr. Richard Penson, Md, MD | Medical Oncology | Boston, MA | $2,000 | $0 |
| Suriya Jeyapalan, M.d, M.D | Neurology | Boston, MA | $1,000 | $0 |
| Dr. Arun Kumar, Md, MD | Hematology & Oncology | Knoxville, TN | $500.00 | $0 |
| Manish Sagar, Md, MD | Internal Medicine | Boston, MA | $425.00 | $0 |
| Dr. Manny Sternberg, M.d, M.D | Surgery | Forest Hills, NY | $400.00 | $0 |
| Dr. Marcel Odaimi, Md, MD | Hematology & Oncology | Salisbury, MD | $400.00 | $0 |
| Inna Shmerlin, M.d,, M.D, | Medical Oncology | Dallas, TX | $400.00 | $0 |
| Felicia Pharagood Wade, Md, MD | Emergency Medicine | Duluth, GA | $384.30 | $0 |
| Khalil Diab, Md, MD | Critical Care Medicine | Washington, DC | $316.67 | $0 |
| Alan Multz, Md, MD | Pulmonary Disease | East Meadow, NY | $291.67 | $0 |
| Frank Fossella, M.d, M.D | Medical Oncology | Houston, TX | $250.00 | $0 |
| Jigar Shah, Md, MD | Hematology & Oncology | Clarksville, TN | $250.00 | $0 |
| Suresh Devineni, M.d, M.D | Hematology & Oncology | Mankato, MN | $250.00 | $0 |
| Rabih Fahed, M.d, M.D | Hematology & Oncology | Norfolk, NE | $250.00 | $0 |
| Dr. Rohan Sharma, M.d, M.D | Hematology & Oncology | Scottsdale, AZ | $250.00 | $0 |
| Dr. James Shen, M.d, M.D | Medical Oncology | Arcadia, CA | $250.00 | $0 |
| Dr. Vladimir Gotlieb, Md, MD | Hematology & Oncology | Forest Hills, NY | $250.00 | $0 |
| Michel Kuzur, Md, MD | Medical Oncology | Nashville, TN | $250.00 | $0 |
Ad
Top Products
- Optune $1.1M
- Optune Lua (NovoTTF-200T) $643.58
Payment Categories
- Food & Beverage $2,312
- Consulting $280,924
- Travel & Lodging $3,112
- Research $13.1M
About Novocure GmbH
Novocure GmbH has made $13.5M in payments to 299 healthcare providers, recorded across 2,128 transactions in the CMS Open Payments database. In 2024, the company paid $4.8M. The top product by payment volume is Optune ($1.1M).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Radiation Oncology ($157,002 to 7 doctors).
Payment categories include: Food & Beverage ($2,312), Consulting ($280,924), Research ($13.1M), Travel & Lodging ($3,112).